These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2063 related articles for article (PubMed ID: 30907320)

  • 1. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
    Dunys J; Valverde A; Checler F
    J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
    Abe K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic changes in Alzheimer's disease and its models.
    Pozueta J; Lefort R; Shelanski ML
    Neuroscience; 2013 Oct; 251():51-65. PubMed ID: 22687952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
    Conway KA; Baxter EW; Felsenstein KM; Reitz AB
    Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease pathogenesis and therapeutic interventions.
    Parihar MS; Hemnani T
    J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches.
    Gholami A
    Neurosci Lett; 2023 Nov; 817():137532. PubMed ID: 37866702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model.
    Zara S; Rapino M; Sozio P; Di Stefano A; Nasuti C; Cataldi A
    Brain Res; 2011 Sep; 1412():79-87. PubMed ID: 21820649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-amyloid, neuronal death and Alzheimer's disease.
    Carter J; Lippa CF
    Curr Mol Med; 2001 Dec; 1(6):733-7. PubMed ID: 11899259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.
    Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH
    Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies.
    Pereira C; Agostinho P; Moreira PI; Cardoso SM; Oliveira CR
    Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):383-403. PubMed ID: 16101556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
    Cai Z; Zhao Y; Zhao B
    Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 104.